Chronic Myeloid Leukemia: Management of Relapse After Allogeneic Bone Marrow Transplantation

References

• Goldman J. M., Apperley J. F., Jones L., et al. Bone marrow transplantation for patients with chronic myeloid leukemia. New England J. Medicine 1986; 314: 202–7
   PubMed Web of Science ®Google Scholar
• Goldman J. M., Gale R. P., Horowitz M. M., et al. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase: Increased risk of relapse associated with T cell depletion. Annals of Int. Medicine 1988; 108: 80614
   Google Scholar
• Bortin M. M., Ringden O., Horowitz M., et al. Temporal relationships between the major complications of bone marrow transplantation for leukemia. Bone Marrow Transplantation 1989; 4: 339–344
   PubMed Web of Science ®Google Scholar
• Cullis J. O., Marks D. I., Schwarer A. P., et al. Relapse into blast crisis following bone marrow transplantation for chronic phase chronic myeloid leukemia. British J. Haematology 1992; 81: 378–382
   PubMed Web of Science ®Google Scholar
• Arthur C. K., Apperley J. F., Guo A. P., et al. Cytogenetic events after marrow transplantation for chronic myeloid leukemia in chronic phase. Blood 1988; 71: 1179–1186
   PubMed Web of Science ®Google Scholar
• Zaccaria A., Rosti G., Testoni N., et al. Cytogenetic events after bone marrow transplantation for Philadelphia chromosome positive chronic myeloid leukemia. Leukemia Research 1991; 15: 289–296
   PubMed Web of Science ®Google Scholar
• Hughes T. P., Morgan G. J., Martiat P., Goldman J. M. Detection of residual leukemia after bone marrow transplant for chronic myeloid leukemia: role of polymerase chain reaction in predicting relapse. Blood 1991; 77: 874878
   Google Scholar
• Hughes T. P., Economou K., Mackinnon S., et al. Slow evolution of chronic myeloid leukemia relapsing after BMT with T cell depleted donor marrow. British J. Haematology 1989; 73: 462467
   Web of Science ®Google Scholar
• Talpaz M., Kantarjian H., Kurzrock R., Trujillo J. M., Gutterman J. V. Interferon alpha produces sustained cytogenetic responses in chronic myelogenous leukemia. Philadelphia chromosome positive patients. Annals of Internal Medicine 1991; 114: 532–538
   PubMed Web of Science ®Google Scholar
• Newland A. C., Jones L., Mir N., Slocombe G. W. Alpha 2 interferon in chronic myeloid leukemia following relapse post allogeneic transplant. British J. Haematology 1987; 66: 141–148
   PubMed Web of Science ®Google Scholar
• Borgies P., Ferrant A., Delannoy A., et al. Interferon alpha induced and maintained complete remission in chronic granulocytic leukemia in relapse after bone marrow transplantation. Bone Marrow Transplantation 1989; 4: 127–128
   PubMed Web of Science ®Google Scholar
• Arcese W., Mauro F. R., Alimena G., et al. Interferon theram. for Ph Dositive CML Datients relamine. after T cell depleted allogeneic bone marrow transplantation. Bone Marrow Transplantarion 1990; 5: 309–315
   PubMed Web of Science ®Google Scholar
• Higano C. S., Raskind W., Durnam D., et al. Interferon-a induces cytogenetic remissions in patients who relapse with chronic myelogenous leukemia (CML) after allogeneic BMT. Experimental Haematology 1990; 18(6)645, abstract.
   Google Scholar
• Steegman J. L., Perez M., Vaquez, et al. Interferon alpha treatment of accelerated phase chronic myeloid leukemia in relapse after bone marrow transplantation; a case with complete cytogenetic and molecular remission. Bone Marrow Transplantation 1991; 7: 65–67
   PubMed Web of Science ®Google Scholar
• Klingemann H. G., Philips G. L. lmmunotherapy after bone marrow transplantation. Bone Marrow Transplantation 1991; 8: 73–81
   PubMed Web of Science ®Google Scholar
• Meyers J. D., Flournoy N., Sanders J. E., et al. Prophylactic use of human leukocyte interferon after allogeneic marrow transplantation. Annals of Internal Medicine 1987; 107: 809–16
   PubMed Web of Science ®Google Scholar
• Klingemann H. G., Grigg A. P., Wilkie Boyd K., et al. Treatment with recombinant interferon (α-2b) early after bone marrow transplantation in patients at high risk for relapse. Blood 1991; 78: 3306–3311
   PubMed Web of Science ®Google Scholar
• Wright S. E., Thomas E. D., Buckner C. D., et al. Experience with second transplants. Experimental Haematology 1976; 4: 221–226
   PubMed Web of Science ®Google Scholar
• Champlin R. E., Ho W. G., Lenarsky C., et al. Successful second marrow transplants for treatment of acute myelogenous leukemia and acute lymphoblastic leukemia. Transplant Proceedings 1985; 17: 496499
   Google Scholar
• Barrett A. J., Joshi R., Tew C., et al. How should acute lymphoblastic leukemia relapsing after bone marrow transplantation be treated?. Loncet 1985; i: 1188–1190
   Google Scholar
• Atkinson K., Biggs J., Concannon A., et al. Second marrow transplants for recurrence of haematological malignancy. Bone Marrow Transplantarion 1986; l: 159–166
   Google Scholar
• Blume K. G., Forman S. J. High dose busulphan/etoposide as a preparatory regimen for second bone marrow transplants in haematological malignancies. Blut 1987; 55: 49–53
   PubMedGoogle Scholar
• Maramont A. M., van Lint M. T., Frassoni F., Bacigalupo A. Second marrow transplants for relapsed leukemia after bone marrow transplantation. Bone Marrow Transplantation 1988; 3%(suppl. 1)332–333
   Google Scholar
• Frassoni F., Barrett A. J., Granena A., et al. Relapse after allogeneic bone marrow transplantation for acute leukemia: a survey by the EBMT of 117 cases. British J. Haematology 1988; 70: 317–20
   PubMed Web of Science ®Google Scholar
• Mortimer J., Blinder M. A., Schulrnan S., et al. Relapse of acute leukemia after marrow transplantation: natural history and results of subsequent therapy. J. Clinical Oncology 1989; 7: 50–57
   PubMed Web of Science ®Google Scholar
• Sanders J. E., Buckner C. D., Clift R. A., et al. Second marrow transplants in patients with leukemia who relapse after allogeneic marrow transplantation. Bone Marrow Transplantation 1988; 3: 11–19
   PubMed Web of Science ®Google Scholar
• Sanders J. E., Buckner C. D., Clift R. A., et al. Second marrow transplants for patients with haematological malignancy who relapsed after first transplant. (abstract). Blood 1989; 74%(supplement)203a
   Google Scholar
• Barrett A. J., Locatelli F., Treleaven J., et al. Second transplants for leukemic relapse after bone marrow transplantation: high mortality but favourable effect of chronic GVHD on continued remission. A report by the EBMT leukemia working party. British J. Haematology 1991; 79: 567–574
   PubMed Web of Science ®Google Scholar
• Cullis J. O., Schwarer A. P., Hughes T. P., et al. Second transplants for patients with chronic myeloid leukemia in relapse after original transplants with T-depleted donor marrow: feasibility of using busulphan alone for reconditioning. Brirish. J. Haemarology 1992; 80: 33–39
   PubMed Web of Science ®Google Scholar
• Wagner J. E., Vogelsang G. B., Zehnbauer B. A., et al. Relapse of leukemia after bone marrow transplantation: effect of second myeloblative therapy. Bone Marrow Transplantation 1992; 9: 205–209
   PubMed Web of Science ®Google Scholar
• Mrsic M., Horowitz M. M., Atkinson K., et al. Second HLA-identical sibling transplants for leukemia recurrence. Bone Marrow Transplanration 1992; 9: 269–275
   PubMed Web of Science ®Google Scholar
• Schattenberg A., Bar B., Preijers F., et al (1992) Treatment of relapse in recipients of lymphocyte depleted bone marrow with retransplantation of unmanipulated grafts or with infusion of donor lymphocytes. Data presented at 18th annual meeting of the European group for Bone Marrow Transplantation at Stockholm, Sweden, June, 1992, (abstract 363).
   Google Scholar
• Sullivan K. M., Storb R., Buckner C. D., et al. Graft versus host disease as adoptive immunotherapy in patients with advanced haematological neoplasms. New England J. Medicine 1989; 320: 828
   PubMed Web of Science ®Google Scholar
• Kolb H. J., Mittermuller J., Clemm Ch., et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 1990; 16: 2462–2465
   Google Scholar
• Cullis J. O., Jiang Y. Z., Schwarer A. P., et al. Donor leukocyte infusions for chronic myeloid leukemia in relapse after allogeneic bone marrow transplantation. Blood 1992; 79: 1379–1381
   PubMed Web of Science ®Google Scholar
• Frassoni F., Fagioli F., Sessarego F., et al (1992) The effect of donor leukocyte infusion for CML patients relapsed after allogeneic BMT. Data presented at 18th annual meeting of the European group for Bone Marrow Transplantation at Stockholm, Sweden, June, 1992, (abstract 248).
   Google Scholar
• Lonnqvist B., Ljungman P., Carneskog A., et al (1992) Treatment of relapsed rnyeloproliferative disease after BMT with donor lymphocytes infusions. Data presented at 18th annual meeting of the European group for Bone Marrow Transplantation at Stockholm, Sweden, June, 1992. Sweden, (abstract 263).
   Google Scholar
• Helg C. I., Soulier Lauper M., Guetty Alberto M., et al (1992) Induction of graft versus leukemia reaction with graft versus host disease for recurrent chronic myelogenous leukemia after T cell depleted allogeneic bone marrow transplantation. Data presented at 18th annual meeting of the European group for Bone Marrow Transplantation at Stockholm, Sweden, June, 1992. Sweden, (abstract 481)
   Google Scholar
• Frassoni F., Sessarego M., Bacigalupo A., et al. Competition between recipient and donor cells after bone marrow transplantation for chronic myloid leukemia. British J. Haematology 1988; 69: 471475
   Web of Science ®Google Scholar
• Palka G., di Bartolomeo P., Lacone, et al. Cytogenetics and bone marrow transplantation. Cancer Genet. Cytogenet. 1987; 21: 147
   Web of Science ®Google Scholar